Previous 10 | Next 10 |
A look at the top 10 most actives in the United States Phunware Inc. (PHUN) rose 19.9% to $0.41 on volume of 260,182,609 shares Palantir Technologies Inc. Class A (PLTR) fell 1.8% to $16.72 on volume of 167,698,349 shares PROSHARES TRUST (SQQQ) rose 0.5% to $11.78 on volume of 155,646,888...
2024-02-05 13:05:53 ET More on Mid-day movers $ stocks. Karyopharm: Approaching The Bottom Ahead Of Earnings And Topline Data (Rating Upgrade) Karyopharm Therapeutics: Promising Potential With 3 Ongoing Phase 3 Studies But Risky Peraso Inc. (PRSO) Q3 2023 Earnings Ca...
2024-02-05 10:00:03 ET More on Health Care Select Sector SPDR Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Lilly, Zoetis, Abbott least shor...
2024-02-05 08:22:25 ET More on Adverum Biotechnologies Seeking Alpha’s Quant Rating on Adverum Biotechnologies Historical earnings data for Adverum Biotechnologies Financial information for Adverum Biotechnologies Read the full article on Seeking Alp...
- Financing led by TCGX with participation from new and existing investors including 5AM Ventures, Commodore Capital, Frazier Life Sciences, Logos Capital, Samsara BioCapital, Venrock Healthcare Capital Partners and Vivo Capital, as well two large investment management firms. - Pro form...
- Preliminary safety and efficacy data from ongoing LUNA Phase 2 study of Ixo-vec for the treatment of wet AMD will be presented at the 47 th Annual Meeting of the Macula Society, with company-sponsored webcast on Thursday, February 8, 2024 at 8:00am ET - REDWOOD CITY, Calif.,...
REDWOOD CITY, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Romuald “Romu” Corbau, Ph.D., has j...
REDWOOD CITY, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced the initial LUNA preliminary efficacy and safety data ...
REDWOOD CITY, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Linda Rubinstein, chief financial officer, and St...
2023-11-09 17:51:02 ET More on Adverum Biotechnologies Adverum: H2 2023 Data Readouts For Wet-AMD Gene Therapy Adverum Biotechnologies appoints Andrew Ramelmeier as chief technology officer Seeking Alpha’s Quant Rating on Adverum Biotechnologies For fu...
News, Short Squeeze, Breakout and More Instantly...
Adverum Biotechnologies Inc. Company Name:
ADVM Stock Symbol:
NASDAQ Market:
- Phase 2 LUNA interim analysis to be presented at ASRS Annual Scientific Meeting on July 17th, 2024 in Stockholm, Sweden - $193.3 million in cash...
- Phase 2 LUNA interim analysis to be presented at ASRS Annual Scientific Meeting on July 17 th , 2024 in Stockholm, Sweden - $193.3 million in cash, cash equivalents and short-term investments expected to fund operations into late 2025 REDWOOD CITY, Calif., May 09, 20...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...